BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.

NEWS: BDSI Completes Acquisition of ELYXYB Learn More >

Report an Adverse Event

To report an adverse event/reaction and/or product complaint to BDSI, call 1-800-469-0261 and select option 1. Or email the information requested below to drugsafety@bdsi.com.

When choosing this option please have the following information ready:

  • Identifiable reporter
  • Identifiable patient (gender)
  • Adverse reaction and/or product complaint
  • Suspect lot number and/or dosing information
  • Callback number and/or email

To report an adverse event/reaction directly to FDA’s MedWatch program, call 1-800-FDA-1088 (1-800-332-1088) or go to www.fda.gov/Safety/MedWatch.

If you wish to be contacted by your local BDSI representative, call 1-800-469-0261 and select option 6.

BDSI routinely collects and analyzes safety information on our products, including reports from healthcare professionals and patients about Adverse Events and Product Complaints. We submit reports as appropriate to the U.S. Food and Drug Administration (FDA) which reviews these reports.

Recent BDSI News

September 30, 2021

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Virtual Event on October 14, 2021 RALEIGH, N.C. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty

Read more
September 9, 2021

Expands Portfolio and Establishes Growth Platform in Neurology The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Commercial Launch Planned for Q1 2022 Investor Day on October 14, 2021 RALEIGH, N.C. , Sept.

Read more
September 7, 2021

RALEIGH, N.C. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA ®  (buprenorphine buccal film), CIII

Read more
More news

Upcoming Events

There are no events to display

Stay Connected

Stay up to date on the latest news

Get started now
October 18, 2021BDSI $4.08/ - 1.75%
Data provided by Nasdaq. Minimum 15 minutes delayed.